Li‐Xu Yan

6.0k total citations · 3 hit papers
63 papers, 4.1k citations indexed

About

Li‐Xu Yan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Li‐Xu Yan has authored 63 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 24 papers in Cancer Research and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Li‐Xu Yan's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Cancer-related molecular mechanisms research (12 papers). Li‐Xu Yan is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Cancer-related molecular mechanisms research (12 papers). Li‐Xu Yan collaborates with scholars based in China, Sweden and United Kingdom. Li‐Xu Yan's co-authors include Jian‐Yong Shao, Yi-Xin Zeng, Ma-Yan Huang, Qiu-Liang Wu, Qiong Shao, Ling Deng, Zhong‐Yi Dong, Yi‐Long Wu, Wen‐Zhao Zhong and Jian Su and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Li‐Xu Yan

55 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis

2008 956 citations Li‐Xu Yan, Ma-Yan Huang et al. profile →
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

2016 741 citations Zhong‐Yi Dong, Wen‐Zhao Zhong et al. Clinical Cancer Research profile →
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

2017 333 citations Zhong‐Yi Dong, Si‐Yang Maggie Liu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Li‐Xu Yan China	26	2.0k	1.9k	1.6k	1.3k	443	63	4.1k
Pratyaksha Wirapati Switzerland	22	2.5k 1.2×	2.2k 1.1×	2.1k 1.3×	761 0.6×	301 0.7×	46	4.6k
Gulisa Turashvili Canada	29	1.9k 1.0×	1.4k 0.7×	1.2k 0.8×	519 0.4×	192 0.4×	109	3.9k
Hualiang Xiao China	27	1.8k 0.9×	993 0.5×	1.1k 0.7×	461 0.4×	554 1.3×	77	3.2k
Hee Jin Lee South Korea	33	1.3k 0.6×	1.0k 0.5×	1.6k 1.0×	453 0.4×	817 1.8×	116	3.3k
Yoon‐La Choi South Korea	35	1.4k 0.7×	1.1k 0.6×	1.6k 1.0×	930 0.7×	342 0.8×	125	3.7k
Tathiane M. Malta Brazil	15	2.0k 1.0×	1.2k 0.6×	768 0.5×	884 0.7×	410 0.9×	37	3.1k
Hege G. Russnes Norway	23	1.6k 0.8×	1.5k 0.8×	1.1k 0.7×	397 0.3×	205 0.5×	55	3.0k
Samer Al‐Saad Norway	36	1.7k 0.9×	1.3k 0.7×	2.3k 1.4×	1.2k 0.9×	1.3k 2.8×	66	4.3k
Päivi Auvinen Finland	28	1.6k 0.8×	901 0.5×	1.6k 1.0×	440 0.4×	509 1.1×	75	3.5k
Marleen Kok Netherlands	30	1.1k 0.5×	887 0.5×	2.3k 1.4×	817 0.7×	953 2.2×	90	3.6k

Countries citing papers authored by Li‐Xu Yan

Since Specialization

Citations

This map shows the geographic impact of Li‐Xu Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li‐Xu Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li‐Xu Yan more than expected).

Fields of papers citing papers by Li‐Xu Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li‐Xu Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li‐Xu Yan. The network helps show where Li‐Xu Yan may publish in the future.

Co-authorship network of co-authors of Li‐Xu Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Li‐Xu Yan. A scholar is included among the top collaborators of Li‐Xu Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li‐Xu Yan. Li‐Xu Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zheng, Kai, Haojie Wang, Honglin Cao, Li‐Xu Yan, & Xiaoju Zhang. (2025). A high-precision PINN method for solving a generalized Burgers–Fisher equation. European Journal of Mechanics - B/Fluids. 114. 204306–204306. 1 indexed citations

Xu, Fangping, et al.. (2024). Feasibility of intraoperative assessment of STAS in pathologic stage 1 lung adenocarcinomas in Chinese patients. European Journal of Surgical Oncology. 51(8). 108747–108747. 2 indexed citations

Lin, Huan, Zaiyi Liu, Li‐Xu Yan, et al.. (2023). Artificial intelligence-quantified tumour-lymphocyte spatial interaction predicts disease-free survival in resected lung adenocarcinoma: A graph-based, multicentre study. Computer Methods and Programs in Biomedicine. 238. 107617–107617. 4 indexed citations

Han, Chu, Jiatai Lin, Yi Wang, et al.. (2022). Multi-layer pseudo-supervision for histopathology tissue semantic segmentation using patch-level classification labels. Medical Image Analysis. 80. 102487–102487. 68 indexed citations

Li, Zhenhui, Xin Chen, Yanqi Huang, et al.. (2021). A radiomics prognostic scoring system for predicting progression-free survival in patients with stage IV non-small cell lung cancer treated with platinum-based chemotherapy. Chinese Journal of Cancer Research. 33(5). 592–605. 11 indexed citations

Yan, Li‐Xu, Yu Zhang, Wei Zhang, Shengqiong Deng, & Zhi‐Ru Ge. (2020). lncRNA-NRF is a Potential Biomarker of Heart Failure After Acute Myocardial Infarction. Journal of Cardiovascular Translational Research. 13(6). 1008–1015. 21 indexed citations

Peng, Xiaoxiao, Li‐Xu Yan, Chao Liu, et al.. (2019). Benign disease prone to be misdiagnosed as malignant pulmonary nodules: Minute meningothelioid nodules. Thoracic Cancer. 10(5). 1182–1187. 11 indexed citations

He, Lan, et al.. (2019). Radiomics-based predictive risk score: A scoring system for preoperatively predicting risk of lymph node metastasis in patients with resectable non-small cell lung cancer. Chinese Journal of Cancer Research. 31(4). 641–652. 32 indexed citations

Su, Shan, Zhong‐Yi Dong, Zhi Xie, et al.. (2018). Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. Journal of Thoracic Oncology. 13(11). 1668–1675. 101 indexed citations

10.

Yan, Li‐Xu, Qianya Qi, Xuan Peng, et al.. (2018). Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. Annals of Surgical Oncology. 25(13). 4037–4046. 33 indexed citations

11.

Han, Jiefei, Qiuyi Zhang, Qing Zhou, et al.. (2017). P3.02b-116 Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI. Journal of Thoracic Oncology. 12(1). S1263–S1264. 1 indexed citations

12.

Li, Qiong, Li‐Xu Yan, Zhou Zhang, et al.. (2017). ALK and ROS1 Double-Rearranged Lung Squamous Cell Carcinoma Responding to Crizotinib Treatment: A Case Report. Journal of Thoracic Oncology. 12(12). e193–e197. 9 indexed citations

13.

Wu, Si-Pei, Ri-Qiang Liao, Hai‐Yan Tu, et al.. (2017). Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Journal of Thoracic Oncology. 13(4). 521–532. 120 indexed citations

14.

Han, Jiefei, Qiuyi Zhang, Qing Zhou, et al.. (2017). JCES01.24 Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TKI. Journal of Thoracic Oncology. 12(1). S240–S241. 1 indexed citations

15.

Dong, Zhong‐Yi, Wen‐Zhao Zhong, Xu‐Chao Zhang, et al.. (2016). Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research. 23(12). 3012–3024. 741 indexed citations breakdown →

16.

Cai, Mu-Yan, Feng-Wei Wang, Chang-Peng Li, et al.. (2016). Prognostic factors affecting postoperative survival of patients with solitary small hepatocellular carcinoma. Chinese Journal of Cancer. 35(1). 80–80. 14 indexed citations

17.

Yan, Li‐Xu, Yan‐Hui Liu, Donglan Luo, et al.. (2014). MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. PLoS ONE. 9(8). e104068–e104068. 65 indexed citations

18.

Zhang, Fen, Li‐Xu Yan, Su-Xia Lin, et al.. (2013). Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups. Diagnostic Pathology. 8(1). 154–154. 3 indexed citations

19.

Zhang, Yan, Li‐Xu Yan, Qi-Nian Wu, et al.. (2011). miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer. Cancer Research. 71(10). 3552–3562. 237 indexed citations

20.

Zhou, Bin, et al.. (2009). Relationship between NFKB1 -94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk. Annals of Oncology. 21(3). 506–511. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact